ImmunityBio, Inc. (IBRX) is the 24th largest of 300 Biotechnology companies by market capitalisation, at 8.48 Bn, behind Vaxcyte, Inc. at 8.83 Bn. The table below compares all 300 on 8 financial metrics.
| # | Ticker | Company | match | industry_code | industry_group | industry_group_code | Market Capitalization | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AMGN | Amgen Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 235.90 Bn | 0.00 Mn | 6.19 | 221.92 Bn |
| 2 | GILD | Gilead Sciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 187.36 Bn | 0.00 Mn | 6.15 | 184.18 Bn |
| 3 | VRTX | Vertex Pharmaceuticals Inc / Ma | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 138.87 Bn | 0.00 Mn | 11.03 | 131.01 Bn |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 85.57 Bn | 0.00 Mn | 5.51 | 77.57 Bn |
| 5 | ARGX | Argenx Se | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 63.51 Bn | 0.00 Mn | 12.15 | 58.32 Bn |
| 6 | MRNA | Moderna, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 58.19 Bn | 0.00 Mn | 26.12 | 53.05 Bn |
| 7 | ALNY | Alnylam Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 35.38 Bn | 0.00 Mn | 7.36 | 32.07 Bn |
| 8 | BIIB | Biogen Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 32.63 Bn | 0.00 Mn | 3.25 | 31.35 Bn |
| 9 | INSM | INSMED Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 27.41 Bn | 0.00 Mn | 24.09 | 26.25 Bn |
| 10 | BNTX | BioNTech SE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 25.24 Bn | 0.00 Mn | 8.16 | 11.59 Bn |
| 11 | ROIV | Roivant Sciences Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 25.22 Bn | 0.00 Mn | 2,309.22 | 25.22 Bn |
| 12 | ASND | Ascendis Pharma A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 16.34 Bn | 0.00 Mn | 13.39 | 15.40 Bn |
| 13 | MDGL | Madrigal Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.77 Bn | 0.00 Mn | 12.28 | 14.93 Bn |
| 14 | BBIO | BridgeBio Pharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 14.58 Bn | 0.00 Mn | 20.45 | 13.86 Bn |
| 15 | SMMT | Summit Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 13.49 Bn | — | — | 12.80 Bn |
| 16 | HALO | Halozyme Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.92 Bn | 0.00 Mn | 7.77 | 12.69 Bn |
| 17 | BMRN | Biomarin Pharmaceutical Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.85 Bn | 0.00 Mn | 3.77 | 11.98 Bn |
| 18 | ARWR | Arrowhead Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.33 Bn | 0.00 Mn | 18.42 | 10.73 Bn |
| 19 | PRAX | Praxis Precision Medicines, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.24 Bn | 0.00 Mn | — | 9.48 Bn |
| 20 | APGE | Apogee Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.18 Bn | 0.00 Mn | — | 9.20 Bn |
| 21 | IONS | Ionis Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.68 Bn | 0.00 Mn | 11.07 | 7.62 Bn |
| 22 | PTGX | Protagonist Therapeutics, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.58 Bn | 0.00 Mn | 33.97 | 9.58 Bn |
| 23 | PCVX | Vaxcyte, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.83 Bn | 0.00 Mn | — | 8.83 Bn |
| 24 | IBRX | ImmunityBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.48 Bn | 0.00 Mn | 51.14 | 8.12 Bn |
| 25 | IMVT | Immunovant, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.14 Bn | 0.00 Mn | — | 8.14 Bn |
| 26 | TGTX | Tg Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.97 Bn | 0.00 Mn | 9.97 | 7.29 Bn |
| 27 | ABVX | Abivax S.A. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.94 Bn | 0.00 Mn | — | 7.94 Bn |
| 28 | SYRE | Spyre Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.47 Bn | 0.00 Mn | — | 7.47 Bn |
| 29 | SRRK | Scholar Rock Holding Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.26 Bn | 0.00 Mn | — | 7.26 Bn |
| 30 | RYTM | Rhythm Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.04 Bn | 0.00 Mn | 29.36 | 6.71 Bn |
| 31 | CGON | CG Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.56 Bn | 0.00 Mn | 1,053.93 | 6.56 Bn |
| 32 | BLRX | BioLineRx Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.46 Bn | 0.00 Mn | 4,640.10 | 6.46 Bn |
| 33 | MIRM | Mirum Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.39 Bn | 0.00 Mn | 10.34 | 5.95 Bn |
| 34 | KNSA | Kiniksa Pharmaceuticals International, plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.09 Bn | 0.00 Mn | 7.24 | 5.56 Bn |
| 35 | COGT | Cogent Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.95 Bn | 0.00 Mn | — | 5.95 Bn |
| 36 | XENE | Xenon Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.93 Bn | 0.00 Mn | — | 5.93 Bn |
| 37 | ORKA | Oruka Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.87 Bn | — | — | 4.14 Bn |
| 38 | DBVT | DBV Technologies S.A. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.86 Bn | 0.00 Mn | 1,167.84 | 5.69 Bn |
| 39 | PTCT | Ptc Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.79 Bn | 0.00 Mn | 5.74 | 3.56 Bn |
| 40 | LGND | Ligand Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.76 Bn | 0.00 Mn | 19.82 | 4.40 Bn |
| 41 | GRFS | Grifols SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.33 Bn | 0.00 Mn | 0.32 | 4.17 Bn |
| 42 | CELC | Celcuity Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.26 Bn | 0.00 Mn | — | 5.26 Bn |
| 43 | ERAS | Erasca, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.04 Bn | 0.00 Mn | — | 5.04 Bn |
| 44 | RADX | Radiopharm Theranostics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.33 Bn | 0.00 Mn | 20,980.03 | 4.33 Bn |
| 45 | DNLI | Denali Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.18 Bn | 0.00 Mn | 1,159.80 | 4.18 Bn |
| 46 | DNTH | Dianthus Therapeutics, Inc. /DE/ | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.11 Bn | — | — | 3.71 Bn |
| 47 | VKTX | Viking Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.03 Bn | 0.00 Mn | — | 4.03 Bn |
| 48 | TLX | Telix Pharmaceuticals Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.02 Bn | — | — | 3.73 Bn |
| 49 | DYN | Dyne Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.01 Bn | 0.00 Mn | — | 4.01 Bn |
| 50 | RLAY | Relay Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.85 Bn | 0.00 Mn | 372.38 | 3.85 Bn |
| 51 | AMLX | Amylyx Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.77 Bn | 0.00 Mn | — | 3.77 Bn |
| 52 | RCUS | Arcus Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.73 Bn | 0.00 Mn | 31.87 | 3.03 Bn |
| 53 | IDYA | IDEAYA Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.66 Bn | 0.00 Mn | 15.64 | 2.83 Bn |
| 54 | ABCL | AbCellera Biologics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.47 Bn | 0.00 Mn | 52.46 | 3.47 Bn |
| 55 | TNGX | Tango Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.38 Bn | 0.00 Mn | 62.89 | 2.37 Bn |
| 56 | IRON | Disc Medicine, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.09 Bn | 0.00 Mn | — | 3.09 Bn |
| 57 | ARQT | Arcutis Biotherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.08 Bn | 0.00 Mn | 6.64 | 2.84 Bn |
| 58 | CLDX | Celldex Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.07 Bn | 0.00 Mn | 19,455.07 | 3.07 Bn |
| 59 | IMNM | Immunome Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.05 Bn | 0.00 Mn | 593.06 | 2.53 Bn |
| 60 | ZLAB | Zai Lab Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.94 Bn | 0.00 Mn | 6.53 | 2.23 Bn |
| 61 | MBX | MBX Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.93 Bn | 0.00 Mn | — | 2.93 Bn |
| 62 | NRIX | Nurix Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.87 Bn | 0.00 Mn | 78.10 | 2.43 Bn |
| 63 | SLS | SELLAS Life Sciences Group, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.62 Bn | 0.00 Mn | — | 2.62 Bn |
| 64 | VERA | Vera Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.58 Bn | 0.00 Mn | — | 2.58 Bn |
| 65 | BCRX | Biocryst Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.54 Bn | 0.00 Mn | 4.75 | 2.19 Bn |
| 66 | NKTR | Nektar Therapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.44 Bn | 0.00 Mn | 44.69 | 1.76 Bn |
| 67 | HCM | HUTCHMED (China) Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.43 Bn | 0.00 Mn | 3.41 | 2.43 Bn |
| 68 | OCUL | Ocular Therapeutix, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.41 Bn | 0.00 Mn | 46.35 | 2.41 Bn |
| 69 | VRDN | Viridian Therapeutics, Inc.\DE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.40 Bn | 0.00 Mn | 33.74 | 2.40 Bn |
| 70 | BHVN | Biohaven Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.37 Bn | 0.00 Mn | — | 2.10 Bn |
| 71 | XTLB | Xtl Biopharmaceuticals Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.27 Bn | 0.00 Mn | — | 2.27 Bn |
| 72 | KOD | Kodiak Sciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.24 Bn | 0.00 Mn | — | 2.24 Bn |
| 73 | URGN | UroGen Pharma Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.21 Bn | 0.00 Mn | 11.72 | 2.10 Bn |
| 74 | RAPP | Rapport Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.21 Bn | 0.00 Mn | 110.49 | 2.21 Bn |
| 75 | GMAB | Genmab A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.18 Bn | 0.00 Mn | 0.34 | 0.68 Bn |
| 76 | ADMA | Adma Biologics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.18 Bn | 0.00 Mn | 4.26 | 2.05 Bn |
| 77 | ZYME | Zymeworks Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.15 Bn | 0.00 Mn | 57.96 | 1.88 Bn |
| 78 | PHVS | Pharvaris N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.15 Bn | 0.00 Mn | — | 1.78 Bn |
| 79 | ZBIO | Zenas BioPharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.08 Bn | 0.00 Mn | 2,075.13 | 2.08 Bn |
| 80 | XNCR | Xencor Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.01 Bn | 0.00 Mn | 19.17 | 1.63 Bn |
| 81 | AGIO | Agios Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.97 Bn | 0.00 Mn | 20.04 | 1.97 Bn |
| 82 | STOK | Stoke Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.96 Bn | 0.00 Mn | 71.02 | 1.67 Bn |
| 83 | RXRX | Recursion Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.94 Bn | 0.00 Mn | 35.38 | 1.39 Bn |
| 84 | VIR | Vir Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.93 Bn | 0.00 Mn | 6.37 | 1.93 Bn |
| 85 | INBX | Inhibrx Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.92 Bn | 0.00 Mn | 1,479.94 | 1.92 Bn |
| 86 | LKFT | Lakefront Biotherapeutics NV | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.89 Bn | 0.00 Mn | 1.63 | 1.89 Bn |
| 87 | TYRA | Tyra Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.88 Bn | 0.00 Mn | — | 1.88 Bn |
| 88 | IMCR | Immunocore Holdings plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.86 Bn | 0.00 Mn | 4.31 | 0.98 Bn |
| 89 | SNDX | Syndax Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.83 Bn | 0.00 Mn | 7.26 | 1.28 Bn |
| 90 | CMPS | COMPASS Pathways plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.79 Bn | 0.00 Mn | — | 1.79 Bn |
| 91 | SCNI | Scinai Immunotherapeutics Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.78 Bn | 0.00 Mn | 1,035.96 | 1.78 Bn |
| 92 | DMRA | Damora Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.78 Bn | 0.00 Mn | — | 1.24 Bn |
| 93 | GHRS | GH Research PLC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.70 Bn | 0.00 Mn | — | 1.34 Bn |
| 94 | NVAX | Novavax Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.67 Bn | 0.00 Mn | 4.05 | 0.96 Bn |
| 95 | SEPN | Septerna, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.66 Bn | 0.00 Mn | 16.83 | 1.66 Bn |
| 96 | ANAB | Anaptysbio, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.62 Bn | 0.00 Mn | 8.13 | 1.33 Bn |
| 97 | ATAI | AtaiBeckley Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.60 Bn | 0.00 Mn | 527.69 | 1.60 Bn |
| 98 | RARE | Ultragenyx Pharmaceutical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.59 Bn | 0.00 Mn | 2.22 | 1.30 Bn |
| 99 | BCAX | Bicara Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | 0.00 Mn | — | 1.58 Bn |
| 100 | FBRX | Forte Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | 0.00 Mn | — | 1.23 Bn |
| 101 | AAPG | Ascentage Pharma Group International | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.57 Bn | 0.00 Mn | 20.12 | 1.29 Bn |
| 102 | MAZE | Maze Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.55 Bn | 0.00 Mn | 77.43 | 1.55 Bn |
| 103 | ANRO | Alto Neuroscience, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.53 Bn | 0.00 Mn | — | 1.53 Bn |
| 104 | AVBP | ArriVent BioPharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.48 Bn | 0.00 Mn | — | 1.48 Bn |
| 105 | REPL | Replimune Group, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.45 Bn | 0.00 Mn | — | 1.45 Bn |
| 106 | ALMS | Alumis Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.43 Bn | 0.00 Mn | 171.46 | 0.92 Bn |
| 107 | GLUE | Monte Rosa Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.42 Bn | 0.00 Mn | 49.37 | 0.79 Bn |
| 108 | ORIC | Oric Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.39 Bn | 0.00 Mn | — | 1.39 Bn |
| 109 | ABSI | Absci Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.39 Bn | 0.00 Mn | 891.17 | 1.19 Bn |
| 110 | OMER | Omeros Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.38 Bn | 0.00 Mn | 35.82 | 1.38 Bn |
| 111 | CGEM | Cullinan Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.37 Bn | 0.00 Mn | — | 1.37 Bn |
| 112 | SVRA | Savara Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.36 Bn | 0.00 Mn | — | 1.36 Bn |
| 113 | VOR | Vor Biopharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.35 Bn | 0.00 Mn | — | 1.35 Bn |
| 114 | CRVS | Corvus Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.34 Bn | 0.00 Mn | — | 1.13 Bn |
| 115 | JANX | Janux Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.28 Bn | 0.00 Mn | 53.13 | 1.28 Bn |
| 116 | MNKD | Mannkind Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | 0.00 Mn | 3.20 | 1.15 Bn |
| 117 | JBIO | Jade Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.21 Bn | 0.00 Mn | — | 1.21 Bn |
| 118 | CLYM | Climb Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.17 Bn | 0.00 Mn | — | 1.17 Bn |
| 119 | MLTX | MoonLake Immunotherapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.10 Bn | 0.00 Mn | — | 0.57 Bn |
| 120 | OKYO | OKYO Pharma Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.06 Bn | 0.00 Mn | — | 1.06 Bn |
| 121 | GERN | Geron Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.02 Bn | 0.00 Mn | 4.19 | 0.72 Bn |
| 122 | ABUS | Arbutus Biopharma Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.02 Bn | 0.00 Mn | 5.59 | 0.92 Bn |
| 123 | MNPR | Monopar Therapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.01 Bn | 0.00 Mn | — | 0.96 Bn |
| 124 | WVE | Wave Life Sciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.99 Bn | 0.00 Mn | 15.12 | 0.62 Bn |
| 125 | ANNX | Annexon, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.98 Bn | 0.00 Mn | — | 0.98 Bn |
| 126 | ARDX | Ardelyx, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.93 Bn | 0.00 Mn | 2.06 | 0.65 Bn |
| 127 | RIGL | Rigel Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.91 Bn | 0.00 Mn | 3.27 | 0.81 Bn |
| 128 | STTK | Shattuck Labs, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.89 Bn | 0.00 Mn | 887.69 | 0.89 Bn |
| 129 | TBPH | Theravance Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.88 Bn | 0.00 Mn | 8.46 | 0.49 Bn |
| 130 | ACRS | Aclaris Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.88 Bn | 0.00 Mn | 106.98 | 0.88 Bn |
| 131 | AVTX | Avalo Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.84 Bn | 0.00 Mn | — | 0.84 Bn |
| 132 | CTMX | CytomX Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.79 Bn | 0.00 Mn | 43.36 | 0.46 Bn |
| 133 | ZURA | Zura Bio Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.78 Bn | 0.00 Mn | — | 0.78 Bn |
| 134 | PHAR | Pharming Group N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.78 Bn | 0.00 Mn | 2.35 | 0.62 Bn |
| 135 | BBOT | BridgeBio Oncology Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.72 Bn | 0.00 Mn | — | 0.50 Bn |
| 136 | AURA | Aura Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.71 Bn | 0.00 Mn | — | 0.64 Bn |
| 137 | IRWD | Ironwood Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.70 Bn | 0.00 Mn | 1.79 | 0.62 Bn |
| 138 | SLN | Silence Therapeutics plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.69 Bn | 0.00 Mn | 1,123.69 | 0.62 Bn |
| 139 | ASMB | Assembly Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.69 Bn | 0.00 Mn | 9.21 | 0.37 Bn |
| 140 | OCS | Oculis Holding AG | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.64 Bn | -0.36 Mn | — | 0.35 Bn |
| 141 | CBIO | Crescent Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.64 Bn | 0.00 Mn | 614.61 | 0.47 Bn |
| 142 | CTNM | Contineum Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.63 Bn | 0.00 Mn | — | 0.63 Bn |
| 143 | ALT | Altimmune, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.63 Bn | 0.00 Mn | — | 0.63 Bn |
| 144 | ARVN | Arvinas, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | 0.00 Mn | 1.92 | 0.04 Bn |
| 145 | VALN | Valneva SE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.59 Bn | 560.67 Mn | 3.53 | 0.45 Bn |
| 146 | TECX | Tectonic Therapeutic, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | 0.00 Mn | — | 0.58 Bn |
| 147 | SGMT | Sagimet Biosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | 0.00 Mn | — | 0.58 Bn |
| 148 | OABI | OmniAb, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.56 Bn | 0.00 Mn | 14.65 | 0.51 Bn |
| 149 | IMUX | Immunic, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.54 Bn | 0.00 Mn | — | 0.54 Bn |
| 150 | PRLD | Prelude Therapeutics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.54 Bn | 0.00 Mn | 24.04 | 0.26 Bn |
| 151 | PRTA | Prothena Corp Public Ltd Co | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.51 Bn | 0.00 Mn | 9.35 | 0.22 Bn |
| 152 | ANL | Adlai Nortye Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.50 Bn | 0.00 Mn | 78.36 | 0.26 Bn |
| 153 | RLMD | Relmada Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | 0.00 Mn | — | 0.49 Bn |
| 154 | CCCC | C4 Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | 0.00 Mn | 14.06 | 0.24 Bn |
| 155 | KMDA | Kamada Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | 0.00 Mn | 2.56 | 0.42 Bn |
| 156 | PBYI | Puma Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | 0.00 Mn | 2.12 | 0.40 Bn |
| 157 | RZLT | Rezolute, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.48 Bn | 0.00 Mn | — | 0.48 Bn |
| 158 | NEUP | Neuphoria Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | 0.00 Mn | — | 0.45 Bn |
| 159 | AVIR | Atea Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | 0.00 Mn | — | 0.47 Bn |
| 160 | DRUG | Bright Minds Biosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | 0.00 Mn | — | 0.23 Bn |
| 161 | ARCT | Arcturus Therapeutics Holdings Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | 0.00 Mn | 15.36 | 0.26 Bn |
| 162 | EVMN | Evommune, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | 0.00 Mn | 44.84 | 0.25 Bn |
| 163 | CMPX | Compass Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | 0.00 Mn | — | 0.44 Bn |
| 164 | BIOA | BioAge Labs, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | 0.00 Mn | 42.13 | 0.44 Bn |
| 165 | ENTA | Enanta Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.41 Bn | 0.00 Mn | 6.29 | 0.22 Bn |
| 166 | EYPT | EyePoint, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | 0.00 Mn | 143.82 | 0.22 Bn |
| 167 | LRMR | Larimar Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | 0.00 Mn | — | 0.24 Bn |
| 168 | WHWK | Whitehawk Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | 0.00 Mn | — | 0.38 Bn |
| 169 | CATX | Perspective Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | 0.00 Mn | — | 0.38 Bn |
| 170 | FHTX | Foghorn Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.35 Bn | 0.00 Mn | 9.45 | 0.28 Bn |
| 171 | ELDN | Eledon Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | 0.00 Mn | — | 0.34 Bn |
| 172 | AGEN | Agenus Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | 0.00 Mn | 2.59 | 0.34 Bn |
| 173 | STRO | Sutro Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.33 Bn | 0.00 Mn | 3.71 | 0.17 Bn |
| 174 | UPB | Upstream Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.33 Bn | 0.00 Mn | 105.23 | 0.33 Bn |
| 175 | EPRX | Eupraxia Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | 0.00 Mn | — | 0.32 Bn |
| 176 | GALT | Galectin Therapeutics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | — | 0.30 Bn |
| 177 | BCYC | Bicycle Therapeutics Plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | 4.88 | 0.30 Bn |
| 178 | TRDA | Entrada Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | 63.61 | 0.30 Bn |
| 179 | SABS | SAB Biotherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | — | 0.30 Bn |
| 180 | ACIU | AC Immune SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | 0.00 Mn | 12.92 | 0.29 Bn |
| 181 | MGNX | Macrogenics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | 0.00 Mn | 1.65 | 0.16 Bn |
| 182 | ALEC | Alector, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | 0.00 Mn | 19.90 | 0.10 Bn |
| 183 | ALXO | Alx Oncology Holdings Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | 0.00 Mn | — | 0.27 Bn |
| 184 | AVXL | Anavex Life Sciences Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | 0.00 Mn | — | 0.15 Bn |
| 185 | ANTX | AN2 Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | 0.00 Mn | — | 0.26 Bn |
| 186 | SRZN | Surrozen, Inc./DE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | 0.00 Mn | 22.53 | 0.26 Bn |
| 187 | CAMP | Camp4 Therapeutics Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | 0.00 Mn | 61.14 | 0.26 Bn |
| 188 | IVVD | Invivyd, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | 0.00 Mn | 4.57 | 0.10 Bn |
| 189 | FIXX | Q32 Bio Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | 0.00 Mn | — | 0.15 Bn |
| 190 | CYDY | CytoDyn Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | 0.00 Mn | — | 0.26 Bn |
| 191 | EQ | Equillium, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | 0.00 Mn | — | 0.25 Bn |
| 192 | PYXS | Pyxis Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | 0.00 Mn | 17.92 | 0.22 Bn |
| 193 | NMRA | Neumora Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | 0.00 Mn | — | 0.24 Bn |
| 194 | CGEN | Compugen Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | 0.00 Mn | 3.26 | 0.16 Bn |
| 195 | YDES | YD Bio Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | 0.00 Mn | 287.04 | 0.24 Bn |
| 196 | GLSI | Greenwich LifeSciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | 0.00 Mn | — | 0.23 Bn |
| 197 | ABOS | Acumen Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | 0.00 Mn | — | 0.23 Bn |
| 198 | FTH | Faeth Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | 0.00 Mn | — | 0.23 Bn |
| 199 | KROS | Keros Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | 0.00 Mn | 6.85 | -0.03 Bn |
| 200 | PRQR | ProQR Therapeutics N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | 0.00 Mn | 10.27 | 0.08 Bn |
| 201 | CHRS | Coherus Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | 0.00 Mn | 4.30 | 0.11 Bn |
| 202 | PEPG | PepGen Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | 0.00 Mn | — | 0.22 Bn |
| 203 | KRRO | Korro Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 0.00 Mn | 90.24 | 0.10 Bn |
| 204 | ADAG | Adagene Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 0.00 Mn | 32.66 | 0.21 Bn |
| 205 | ARMP | Armata Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 0.00 Mn | — | 0.19 Bn |
| 206 | PLX | Protalix BioTherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 0.00 Mn | 2.63 | 0.17 Bn |
| 207 | ADCT | ADC Therapeutics SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 0.00 Mn | 2.76 | -0.01 Bn |
| 208 | ORMP | Oramed Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 0.00 Mn | — | 0.21 Bn |
| 209 | NBP | NovaBridge Biosciences | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | 0.00 Mn | — | 0.20 Bn |
| 210 | IPHA | Innate Pharma SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | 0.00 Mn | 60.95 | 0.19 Bn |
| 211 | QNCX | Quince Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | 0.00 Mn | — | 0.19 Bn |
| 212 | OKUR | OnKure Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | 0.00 Mn | — | 0.00 Bn |
| 213 | XLO | Xilio Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | 0.00 Mn | 2.73 | 0.04 Bn |
| 214 | CUE | Cue Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | 0.00 Mn | 7.71 | 0.16 Bn |
| 215 | NGEN | Nervgen Pharma Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | 0.00 Mn | — | 0.17 Bn |
| 216 | MIST | Milestone Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | — | — | 0.00 Bn |
| 217 | RANI | Rani Therapeutics Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | 0.00 Mn | 33.70 | 0.16 Bn |
| 218 | MOLN | Molecular Partners Ag | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | 0.00 Mn | 28.43 | 0.16 Bn |
| 219 | ENTX | Entera Bio Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | 0.00 Mn | — | 0.14 Bn |
| 220 | MDWD | MediWound Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | 0.00 Mn | 12.82 | 0.12 Bn |
| 221 | IFRX | InflaRx N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | 0.00 Mn | 1,890.67 | -0.04 Bn |
| 222 | SPRB | Spruce Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | 0.00 Mn | — | 0.14 Bn |
| 223 | UNCY | Unicycive Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | 0.00 Mn | — | 0.14 Bn |
| 224 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | — | — | -0.03 Bn |
| 225 | IBIO | iBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | 0.00 Mn | 1,373.59 | 0.14 Bn |
| 226 | HURA | TuHURA Biosciences, Inc./NV | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | 0.00 Mn | — | 0.13 Bn |
| 227 | MSLE | Satellos Bioscience Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | 0.00 Mn | — | 0.13 Bn |
| 228 | RFL | Rafael Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | 0.00 Mn | 133.04 | 0.13 Bn |
| 229 | NRXP | NRX Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | 0.00 Mn | 37.84 | 0.10 Bn |
| 230 | BDTX | Black Diamond Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | 0.00 Mn | — | 0.01 Bn |
| 231 | CNTB | Connect Biopharma Holdings Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | 0.00 Mn | 40.91 | 0.12 Bn |
| 232 | TLSA | Tiziana Life Sciences Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | 0.00 Mn | — | 0.12 Bn |
| 233 | PMN | ProMIS Neurosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | 0.00 Mn | — | 0.06 Bn |
| 234 | INO | Inovio Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | 0.00 Mn | — | 0.11 Bn |
| 235 | GNLX | GENELUX Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | 0.00 Mn | — | 0.11 Bn |
| 236 | COYA | Coya Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | 0.00 Mn | 13.53 | 0.07 Bn |
| 237 | ONCY | Oncolytics Biotech Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | 0.00 Mn | — | 0.10 Bn |
| 238 | RLYB | Rallybio Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | 0.00 Mn | 149.31 | 0.10 Bn |
| 239 | PLYX | Polaryx Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | 0.00 Mn | — | 0.08 Bn |
| 240 | KLRS | Kalaris Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | — | 0.09 Bn |
| 241 | OTLK | Outlook Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | — | 0.08 Bn |
| 242 | KZIA | Kazia Therapeutics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | — | — | 0.09 Bn |
| 243 | ALDX | Aldeyra Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | — | 0.09 Bn |
| 244 | ACRV | Acrivon Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | — | 0.09 Bn |
| 245 | CTOR | Citius Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | 55.22 | 0.09 Bn |
| 246 | PYPD | PolyPid Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | — | 0.08 Bn |
| 247 | RVRC | Revium Rx. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | — | 0.09 Bn |
| 248 | FBIO | Fortress Biotech, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | 1.25 | -0.11 Bn |
| 249 | DWTX | Dogwood Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 0.00 Mn | — | 0.08 Bn |
| 250 | MAIA | MAIA Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 0.00 Mn | — | 0.05 Bn |
| 251 | ATHE | Alterity Therapeutics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 0.00 Mn | — | 0.05 Bn |
| 252 | GANX | Gain Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 0.00 Mn | — | 0.08 Bn |
| 253 | INDP | Indaptus Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 0.00 Mn | — | 0.06 Bn |
| 254 | CRDF | Cardiff Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 0.00 Mn | 126.21 | 0.07 Bn |
| 255 | TELO | Telomir Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 0.00 Mn | — | 0.07 Bn |
| 256 | SPRO | Spero Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 0.00 Mn | 1.49 | 0.02 Bn |
| 257 | XBIT | XBiotech Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 0.00 Mn | — | 0.07 Bn |
| 258 | HRTX | Heron Therapeutics, Inc. /De/ | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 0.00 Mn | 0.43 | 0.02 Bn |
| 259 | ALGS | Aligos Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 0.00 Mn | 17.04 | 0.03 Bn |
| 260 | SCYX | Scynexis Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 0.00 Mn | 3.26 | -0.05 Bn |
| 261 | RNTX | Rein Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 0.00 Mn | — | 0.06 Bn |
| 262 | IBO | Impact Biomedical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 0.00 Mn | 1,617.01 | 0.06 Bn |
| 263 | MCRB | Seres Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 0.00 Mn | 29.23 | 0.06 Bn |
| 264 | IMMP | IMMUTEP Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | 5.23 | 0.00 Bn |
| 265 | TIL | Instil Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | — | 0.05 Bn |
| 266 | NMAD | Nomad Power Solutions, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | — | 0.05 Bn |
| 267 | PTN | Palatin Technologies Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | 3.82 | 0.05 Bn |
| 268 | ATYR | aTYR PHARMA INC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | 294.15 | -0.01 Bn |
| 269 | ELTX | Elicio Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | — | 0.02 Bn |
| 270 | HOWL | Werewolf Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | 2.20 | 0.05 Bn |
| 271 | EDSA | Edesa Biotech, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | — | 0.04 Bn |
| 272 | SER | Serina Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | 326.44 | 0.02 Bn |
| 273 | MREO | Mereo BioPharma Group plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | 83.60 | 0.04 Bn |
| 274 | NXTC | NextCure, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | — | 0.04 Bn |
| 275 | IMA | ImageneBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | — | — | -0.09 Bn |
| 276 | APLM | Apollomics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | 4.72 | 0.04 Bn |
| 277 | FLNA | Filana Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | — | 0.04 Bn |
| 278 | LITS | Lite Strategy, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | — | 0.03 Bn |
| 279 | KYNB | Kyntra Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 4.60 | 0.03 Bn |
| 280 | CNTX | Context Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 281 | BHST | Bioharvest Sciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 0.93 | 0.02 Bn |
| 282 | ATNM | Actinium Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 0.93 | 0.03 Bn |
| 283 | BETRF | BetterLife Pharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 284 | ADIL | Adial Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 285 | KAPA | Kairos Pharma, LTD. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 0.35 | 0.03 Bn |
| 286 | BRNS | Barinthus Biotherapeutics plc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 287 | IGC | IGC Pharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 93.50 | 0.03 Bn |
| 288 | CLRB | Cellectar Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 289 | TAOX | TAO Synergies Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 37.05 | 0.03 Bn |
| 290 | RAPH | Raphael Pharmaceutical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 291 | VRXA | Veraxa Biotech AG - Post de-SPAC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 755.61 | 0.02 Bn |
| 292 | NNVC | Nanoviricides, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | 0.02 Bn |
| 293 | ABVC | Abvc Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | 0.02 Bn |
| 294 | LTRN | Lantern Pharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | 0.02 Bn |
| 295 | GRDX | GridAI Technologies Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | 239.09 | 0.02 Bn |
| 296 | EVAX | Evaxion A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | 2.64 | 0.02 Bn |
| 297 | JSPR | Jasper Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | 0.02 Bn |
| 298 | CNSY | Cerenome, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | 4.53 | 0.01 Bn |
| 299 | DYAI | Dyadic International Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | 4.82 | 0.02 Bn |
| 300 | KTTA | Pasithea Therapeutics Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | 0.02 Bn |